Results
|
|
1.
|
The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. MedStar authors:
Year: 2016
Citation: - Breast Cancer Research & Treatment. 155(2):235-51, 2016 Jan.
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Amiri-Kordestani L, Chavez KJ, Conway CM, Dine JL, Greer YE, Hewitt SM, Lipkowitz S, Merchant AS, O'Sullivan CC, Sinclair S, Steinberg SM, Stone B, Swain SM, Voeller D
|
|
|
2.
|
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41. MedStar authors:
Year: 2023
Citation: - Breast Cancer Research & Treatment. 199(2):243-252, 2023 Jun.
Department:
- Associate Dean for Research Development
- MedStar Health
Medline publication type:
- Journal Article
- Randomized Controlled Trial
All authors: - Azar CA, Baez-Diaz L, Bandos H, Bear HD, Boileau JF, Brufsky AM, Geyer CE Jr Hassan S, Magrinat GC, Mamounas EP, Paik S, Rastogi P, Sarwar S, Shibata HR, Suga JM, Swain SM, Tang G, Wolmark N, Yothers G
|
|
|
3.
|
Twenty-five year results of the national cancer institute randomized breast conservation trial. MedStar authors:
Year: 2012
Citation: - Breast Cancer Research & Treatment. 132(1):197-203, 2012 Feb.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - Camphausen K, Dan T, Danforth DN, Glatstein E, Lippman ME, Lita E, Sciuto L, Shih J, Simone NL, Smith SL, Swain SM
|
|
|
4.
|
Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study. [] MedStar authors:
Year: 2015
Citation: - Breast Cancer Research & Treatment. 149(1):163-9, 2015 Jan.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase II
- Journal Article
- Research Support, Non-U.S. Gov't
All authors: - Bhatt K, Bury MJ, Fehrenbacher L, Flynn PJ, Geyer CE Jr, Goel R, Jacobs SA, Johannes H, Julian TB, Mamounas EP, Provencher L, Rastogi P, Robidoux A, Stella PJ, Swain SM, Tan AR, Thirlwell MP, Wolmark N
|
|
|
5.
|
Correction to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology). MedStar authors:
Year: 2022
Citation: - Breast Cancer Research & Treatment. 193(3):565, 2022 Jun.
Department:
- Associate Dean for Research Development
- MedStar Health
Medline publication type:
All authors: - Baez-Diaz L, Bandos H, Brufsky AM, Carolla RL, Fehrenbacher L, Geyer CE Jr, Hamm JT, Jacobs SA, Julian TB, Mamounas EP, Paterson AHG, Polikoff J, Provencher L, Rastogi P, Robidoux A, Swain SM, Ward PJ, Wolmark N
|
|
|
6.
|
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). MedStar authors:
Year: 2013
Citation: - Breast Cancer Research & Treatment. 142(1):89-99, 2013 Nov.
Institution: - Washington Cancer Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Amadori D, Baselga J, Clark E, Knott A, Miles D, Ross G, Semiglazov V, Sunpaweravong P, Swain SM
|
|
|
7.
|
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41. MedStar authors:
Year: 2023
Citation: - Breast Cancer Research & Treatment. 2023 Mar 22
Department:
- Associate Dean for Research Development
- MedStar Health
Medline publication type:
All authors: - Rastogi P, Tang G, Hassan S, Geyer CE Jr, Azar CA, Magrinat GC, Suga JM, Bear HD, Baez-Diaz L, Sarwar S, Boileau JF, Brufsky AM, Shibata HR, Bandos H, Paik S, Yothers G, Swain SM, Mamounas EP, Wolmark N
|
|
|
8.
|
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology). MedStar authors:
Year: 2022
Citation: - Breast Cancer Research & Treatment. 2022 Mar 01
Department:
- Associate Dean for Research Development
- MedStar Health
Medline publication type:
All authors: - Baez-Diaz L, Bandos H, Brufsky AM, Carolla RL, Fehrenbacher L, Geyer CE Jr, Hamm JT, Jacobs SA, Julian TB, Mamounas EP, Paterson AHG, Polikoff J, Provencher L, Rastogi P, Robidoux A, Swain SM, Ward PJ, Wolmark N
|
|
|
9.
|
Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway. MedStar authors:
- Lynce, Filipa
- Swain, Sandra M
Year: 2020
Citation: - Breast Cancer Research & Treatment. 184(2):265-275, 2020 Nov.
Institution: - Washington Cancer Institute
Department:
- Associate Dean for Research Development
- MedStar Health
Medline publication type:
All authors: - Elliott A, Heeke AL, Isaacs C, Korn WM, Lynce F, Pohlmann PR, Schwartzberg LS, Swain SM, Tan AR, Vidal G, Xiu J
|
|
|
10.
|
HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane. MedStar authors:
- Kurian, Shweta
- Mohebtash, Mahsa
- Ottaviano, Yvonne
- Rao, Suman
- Swain, Sandra M
Year: 2022
Citation: - Breast Cancer Research & Treatment. 196(3):571-581, 2022 Dec.
Institution: - MedStar Franklin Square Medical Center
Department:
- Associate Dean for Research Development
- Hematology/Oncology
- MedStar Health
Medline publication type:
- Clinical Trial, Phase II
- Journal Article
- Randomized Controlled Trial
All authors: - Dilawari A, Graham D, Isaacs C, Kurian S, Lynce F, Mainor C, McNamara D, Mohebtash M, Ottaviano Y, Pohlmann PR, Rao S, Swain SM, Swanson N, Tan M, Warren R, Wu T
|
|
|
11.
|
Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines. MedStar authors:
- Asch, Federico M
- Barac, Ana
- Herbolsheimer, Pia M
- Lynce, Filipa
- Mete, Mihriye
- Nunes, Raquel
- Shara, Nawar M
- Swain, Sandra M
- Wray, Lynette
Year: 2016
Citation: - Breast Cancer Research & Treatment. 155(2):285-93, 2016 Jan.
Institution:
- MedStar Health Research Institute
- MedStar Health Research Institute
- MedStar Health Research Institute
- MedStar Washington Hospital Center
- MedStar Washington Hospital Center
- Washington Cancer Institute
- Washington Cancer Institute
- Washington Cancer Institute A
- Washington Cancer Instituteia
Department:
- MedStar Heart Institute
- MedStar Heart Institute
Medline publication type:
All authors: - Asch FM, Barac A, Herbolsheimer P, Isaacs C, Lynce F, Mete M, Nardacci MP, Nunes RA, Peshkin BN, Shara NM, Smith KL, Swain SM, Warren R, Wray L
|
|
|
12.
|
Take care of your neighborhood. MedStar authors:
- Huerta, Elmer E
- Swain, Sandra M
- Weeks-Coulthurst, Patricia
- Williams, Courtney
Year: 2018
Citation: - Breast Cancer Research & Treatment. 167(1):225-234, 2018 01.
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Huerta EE, Swain SM, Weeks-Coulthurst P, Williams C
|
|
|
13.
|
Genomic profiling of breast cancer in African-American women using MammaPrint. MedStar authors:
- Boisvert, Marc E
- Herbolsheimer, Pia M
- Mete, Mihriye
- Nunes, Raquel
- Swain, Sandra M
- Wray, Lynette
Year: 2016
Citation: - Breast Cancer Research & Treatment. 159(3):481-8, 2016 Oct
Institution:
- MedStar Health Research Institute
- Washington Cancer Institute
Medline publication type:
All authors: - Bijelic L, Boisvert ME, Herbolsheimer P, Mete M, Nunes RA, Smith KL, Swain SM, Wray L
|
|
|
14.
|
Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function. MedStar authors:
- Asch, Federico M
- Barac, Ana
- Gallagher, Christopher
- Hofmeyer, Mark
- Lynce, Filipa
- Srichai, Monvadi B
- Swain, Sandra M
Year: 2021
Citation: - Breast Cancer Research & Treatment. 2021 Jan 05
Institution:
- MedStar Heart & Vascular Institute
- Washington Cancer Institute
Department:
- Associate Dean for Research Development
- MedStar Health
Medline publication type:
All authors: - Asch F, Barac A, Dang C, Gallagher C, Geng X, Herbolsheimer P, Hofmeyer M, Isaacs C, Khoury K, Lynce F, Nunes R, Pohlmann PR, Smith KL, Srichai MB, Swain SM, Tan M, Warren R, Yu AF
|
|
|
15.
|
Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. MedStar authors:
- Asch, Federico M
- Barac, Ana
- Cunningham, A
- Gallagher, Christopher
- Hofmeyer, Mark
- Srichai, M B
- Swain, Sandra M
Year: 2019
Citation: - Breast Cancer Research & Treatment. 175(3):595-603, 2019 Jun.
Institution:
- MedStar Health
- MedStar Health Research Institute
- MedStar Heart & Vascular Institute
- Washington Cancer Institute
Department: - Associate Dean for Research Development
Medline publication type:
All authors: - Asch FM, Barac A, Cunningham A, Dang C, Gallagher C, Geng X, Herbolsheimer P, Hofmeyer M, Isaacs C, Lynce F, Nunes R, Pohlmann PR, Shajahan-Haq A, Smith KL, Srichai MB, Swain SM, Tan MT, Timothee P, Warren R, Yu AF
|
